Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas.
Cabergoline
Dopamine agonists
NFPA
Non-functioning pituitary adenoma
Transsphenoidal Surgery
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
08 Dec 2023
08 Dec 2023
Historique:
accepted:
14
11
2023
medline:
8
12
2023
pubmed:
8
12
2023
entrez:
8
12
2023
Statut:
aheadofprint
Résumé
The treatment strategy of non-functioning pituitary adenomas (NFPAs) includes surgery, radiotherapy, medical therapy, or observation without intervention. Cabergoline, a dopaminergic agonist, was suggested for the treatment of NFPA remnants after trans-sphenoidal surgery. This study investigates the efficacy of cabergoline in surgery-naive patients with NFPA. Retrospective cohort study including surgery-naive patients with NFPA ≥ 10 mm, treated with cabergoline at a dose of ≥ 1 mg/week for at least 24 months. Patients with chiasmal damage were excluded. Data collected included symptoms, in particular visual disturbances, hormonal levels, tumor characteristics and size evaluated by MRI. Tumor growth was defined as an increase in maximal diameter of ≥ 2 mm, and shrinkage as reduction of ≥ 2 mm. Our cohort included 25 patients treated with cabergoline as primary therapy. Mean age was 63.3 ± 17.3 years, 56% (14/25) were males. Mean tumor size at diagnosis was 18.6 ± 6.3 mm (median 17 mm, range 10-36), and the average follow-up period with cabergoline was 4.6 ± 3.4 years. Out of the 25 tumors, five tumors (20%) decreased in size (mean decrease of 5.0 ± 3.0 mm), 12 tumors (48%) remained stable, and eight (32%) increased in size (mean growth of 5.0 ± 3.3 mm) with cabergoline treatment. During the first two years of cabergoline treatment, the median tumor size exhibited a reduction of 0.5 mm. Patients with an increase in tumor size had larger adenomas at diagnosis and a longer follow-up. Two patients (8%) underwent surgery due to tumor enlargement. Primary treatment with cabergoline is a reasonable approach for selected patients with NFPAs without visual threat.
Identifiants
pubmed: 38064148
doi: 10.1007/s11102-023-01365-w
pii: 10.1007/s11102-023-01365-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of Pituitary adenomas: a cross-sectional study in the Province of Liège, Belgium. J Clin Endocrinol Metabolism 91(12):4769–4775. https://doi.org/10.1210/jc.2006-1668
doi: 10.1210/jc.2006-1668
Ferrante E, Ferraroni M, Castrignanò T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG (2006) Non-functioning Pituitary Adenoma database: a useful resource to improve the Clinical Management of Pituitary tumors. eur j Endocrinol 155(6):823–829. https://doi.org/10.1530/eje.1.02298
doi: 10.1530/eje.1.02298
pubmed: 17132751
Molitch ME, Pituitary, Incidentalomas (2009) Best Pract Res Clin Endocrinol Metab 23(5):667–675. https://doi.org/10.1016/j.beem.2009.05.001
doi: 10.1016/j.beem.2009.05.001
pubmed: 19945030
Huang W, Molitch ME (2018) Management of nonfunctioning pituitary adenomas (NFAs): Observation. Pituitary 21(2):162–167. https://doi.org/10.1007/s11102-017-0856-0
doi: 10.1007/s11102-017-0856-0
pubmed: 29280025
Yavropoulou MP, Tsoli M, Barkas K, Kaltsas G, Grossman A (2020) The natural history and treatment of non-functioning Pituitary Adenomas (Non-functioning PitNETs). Endocrine-related Cancer 27(10):R375–R390. https://doi.org/10.1530/ERC-20-0136
doi: 10.1530/ERC-20-0136
pubmed: 32674070
Molitch ME (2014) Nonfunctioning pituitary tumors. In handbook of clinical neurology. Elsevier 124:167–184. https://doi.org/10.1016/B978-0-444-59602-4.00012-5
doi: 10.1016/B978-0-444-59602-4.00012-5
Greenman Y, Stern N (2015) Optimal management of non-functioning pituitary adenomas. Endocrine 50(1):51–55. https://doi.org/10.1007/s12020-015-0685-8
doi: 10.1007/s12020-015-0685-8
pubmed: 26179179
Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, Yuan X, Gertych A, Shimon I, Ram Z, Melmed S, Stern N (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175(1):63–72. https://doi.org/10.1530/EJE-16-0206
doi: 10.1530/EJE-16-0206
pubmed: 27150495
Dekkers OM, Hammer S, de Keizer RJW, Roelfsema F, Schutte PJ, Smit JWA, Romijn JA, Pereira AM (2007) The natural course of non-functioning Pituitary Macroadenomas. eur j Endocrinol 156(2):217–224. https://doi.org/10.1530/eje.1.02334
doi: 10.1530/eje.1.02334
pubmed: 17287411
Lenders N, Ikeuchi S, Russell AW, Ho KK, Prins JB, Inder WJ (2016) Longitudinal evaluation of the natural history of conservatively managed nonfunctioning pituitary adenomas. Clin Endocrinol 84(2):222–228. https://doi.org/10.1111/cen.12879
doi: 10.1111/cen.12879
Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JAH (2007) What is the natural history of Nonoperated Nonfunctioning Pituitary Adenomas? Clin Endocrinol 67(6):938–943. https://doi.org/10.1111/j.1365-2265.2007.02990.x
doi: 10.1111/j.1365-2265.2007.02990.x
Ayalon-Dangur I, Robenshtok E, Duskin‐Bitan H, Tsvetov G, Gorshtein A, Akirov A, Shimon I (2023) Natural history of nonfunctioning Pituitary macroadenomas followed without intervention: a retrospective cohort study. Clin Endocrinol 98(4):559–566. https://doi.org/10.1111/cen.14877
doi: 10.1111/cen.14877
Fernández-Balsells MM, Murad MH, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Pérez L, de Ponce PG, Erwin PJ, Carey J, Montori VM (2011) Natural history of nonfunctioning Pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metabolism 96(4):905–912. https://doi.org/10.1210/jc.2010-1054
doi: 10.1210/jc.2010-1054
Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, Fernández-Balsells MM, Bagatto A, Coto-Yglesias F, Carey J, Elraiyah TA, Erwin PJ, Gandhi GY, Montori VM, Murad MH (2012) Treatment of hyperprolactinemia: a systematic review and Meta-analysis. Syst Rev 1(1):33. https://doi.org/10.1186/2046-4053-1-33
doi: 10.1186/2046-4053-1-33
pubmed: 22828169
pmcid: 3483691
Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV, Gasparetto EL, de Castro M, Takiya CM, Gadelha MR (2015) Dopamine receptor subtype 2 expression Profile in Nonfunctioning Pituitary adenomas and in vivo response to Cabergoline Therapy. Clin Endocrinol 82(5):739–746. https://doi.org/10.1111/cen.12684
doi: 10.1111/cen.12684
Batista RL, Musolino NRC, Cescato VAS, da Silva GO, Medeiros RSS, Herkenhoff CGB, Trarbach EB, Cunha-Neto (2019) M. B. Cabergoline in the management of residual nonfunctioning pituitary adenoma: a Single-Center, Open-Label, 2-Year randomized clinical trial. Am J Clin Oncol 42(2):221–227. https://doi.org/10.1097/COC.0000000000000505
doi: 10.1097/COC.0000000000000505
pubmed: 30540568
Vargas-Ortega G, González-Virla B, Balcázar-Hernández L, Arreola-Rosales R, Benitez-Rodríguez FJ, Félix BL, Mercado M (2022) Efficacy of Cabergoline Therapy in patients with non-functioning pituitary adenomas: a single Center Clinical Experience. Archives of Endocrinology and Metabolism. https://doi.org/10.20945/2359-3997000000495
doi: 10.20945/2359-3997000000495
pubmed: 35758837
pmcid: 10697635
Garcia EC, Naves LA, Silva AO, de Castro LF, Casulari LA, Azevedo MF (2013) Short-term treatment with Cabergoline Can lead to Tumor Shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 16(2):189–194. https://doi.org/10.1007/s11102-012-0403-y
doi: 10.1007/s11102-012-0403-y
pubmed: 22740242
Ertekin T, Acer N, Turgut AT, Aycan K, Ozçelik O, Turgut M (2011) Comparison of three methods for the estimation of the Pituitary gland volume using magnetic resonance imaging: a Stereological Study. Pituitary 14(1):31–38. https://doi.org/10.1007/s11102-010-0254-3
doi: 10.1007/s11102-010-0254-3
pubmed: 20809112